



Introduction to STADA

A leading provider of healthcare products in Europe and beyond



Important Notice

This presentation has been prepared by Nidda German Topco GmbH (the “Company”) and its subsidiaries, including STADA Arzneimittel Aktiengesellschaft (collectively, the “Group”), and shall mean and include the following slides, any oral presentation of the slides by the Company or any person on its behalf, any question and answer, hard copies of this document and any other written or oral material discussed or distributed during or in connection with the presentation (together being the “Presentation”). By reading the Presentation, or attending the meeting at which this Presentation is made, or dialing into the teleconference during which the Presentation is made, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in the Presentation concerning the Group has been obtained from the Company and other sources. The Presentation is not the product of research, has not been subject to any independent audit or review, is being provided for information purposes only and may not be relied upon by any person. The information contained in this Presentation has not been subject to any independent audit or review and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information contained in the Presentation should be considered in the context of the circumstances prevailing at the time and will not be updated to reflect material developments that may occur after the date of the Presentation. The information and opinions in this Presentation are provided as of April 22, 2024 and are subject to change without notice. It is not the intention to provide, and you may not rely on this Presentation as providing, a complete or comprehensive analysis of the financial or trading position or prospects of the Company or the Group. A significant portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. The internal estimates have not been verified by an external expert, and it cannot be guaranteed that a third party using different methods to assemble, analyze or compute market information and data would obtain or generate the same results. Neither the Company nor its advisors have verified the accuracy of such information, data or predictions contained in the Presentation that were taken or derived from industry publications, public documents of our competitors or other external sources. In addition, past performance of the Company is not indicative of future performance.

No liability is accepted by any party whatsoever in connection with the contents of this Presentation, including without limitation the Company and any direct or indirect holding company or subsidiary of the Company, and each of their respective investors, advisors (the “Advisors”), affiliates, directors, agents and employees. No person undertakes any obligation to update or revise any information contained in this Presentation based on new information, future events or otherwise. For the avoidance of doubt, none of the Advisors (i) shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this Presentation or its contents; (ii) assumes any obligation for independently verifying the accuracy of any information provided in this Presentation and disclaims any liability with respect to the information herein; and/or (iii) assumes any obligation to update or correct any information herein in each case to the extent legally permissible. The Company, its investors, advisors, affiliates, directors, agents and employees, including their respective representatives, expressly disclaim any and all responsibility or liability that is based on the opinions, information, projections and statements or any part thereof contained in this Presentation, or any other material provided in connection with this Presentation.

Statements herein, other than statements of historical fact, regarding future events or prospects are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of control of the management of the Company. The words “may”, “will”, “should”, “expect”, “anticipate”, “believe”, “estimate”, “plan”, “predict”, “intend” or variations of these words, as well as other statements regarding matters that are not historical fact or regarding future events or prospects, constitute forward-looking statements. The Company has based these forward-looking statements on its current views with respect to future events and financial performance. These views involve significant risks and uncertainties, which could cause actual results to differ materially from those predicted in the forward-looking statements and from the past performance of the Company. As a result, you should not rely on these forward-looking statements. All information, statements, projections and opinions contained in the Presentation do not purport to be comprehensive and are subject to change without notice. Neither the Company nor any other person undertakes any obligation to update or revise any information or statement contained herein, whether as a result of new information, future events or otherwise. The Presentation also includes rounded information. Due to rounding, numbers presented in this Presentation may not add up precisely to the total provided and percentages may not precisely reflect the absolute figures.

This Presentation includes certain consolidated financial information of the Company and, in addition, includes certain financial measures that are not recognized by IFRS or any other generally accepted accounting principles and that may not be permitted to appear on the face of financial statements or footnotes thereto (“Non-GAAP Measures”), including EBITDA / adjusted EBITDA. Non-GAAP Measures should not be considered as alternatives to performance measures derived in accordance with IFRS or any other generally accepted accounting principles, may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools. Non-GAAP Measures may not be comparable to those of other companies in the same industry and may be calculated differently from similar measurements presented by other companies in the same industry. On October 2, 2023, the Group announced that it had transferred its Russian business activities to Nidda Lynx S.à r.l., a subsidiary of an indirect parent entity of the Company, pursuant to an internal Reorganization (the “Reorganization”). As a result, this Presentation includes selected unaudited condensed consolidated financial information of the Company as of and for the year ended December 31, 2023 and the twelve months ended December 30, 2022, in which the Company’s Russian business activities have been presented as discontinued operations and the Company’s results have been retroactively restated, as required pursuant to IFRS. In addition, this Presentation includes selected unaudited condensed consolidated financial information of the Company as of and for the years ended December 31, 2019, 2020, 2021 and 2022, which has been restated on the same basis (the “As Adjusted Financial Information”). The As Adjusted Financial Information has been prepared for illustrative purposes only and does not purport to indicate the financial position or operating results of the Company had the Reorganization actually occurred as of the date or at the beginning of the periods presented. The As Adjusted Financial Information has not been prepared in accordance with IFRS, the requirements of Regulation S-X under the U.S. Securities Act of 1933, as amended (the “Securities Act”), the Prospectus Regulation or any other generally accepted accounting standards. Neither the assumptions underlying the adjustments nor the resulting As Adjusted Financial Information have been audited or reviewed in accordance with any generally accepted auditing standards. During the periods presented in this Presentation the Company completed several acquisitions and dispositions. Consequently, the results of operations in the periods presented in this Presentation may not be directly comparable.

The financial information of the Company as of and for the year ended December 31, 2023 has not been audited or reviewed by our auditors, is not required by or presented in accordance with IFRS or any other generally accepted accounting principles and has been prepared for illustrative purposes only. This information is not necessarily representative of our results of operations for such a period or any future period or any financial position at any past or future date. In addition, certain financial information shown in this Presentation is taken from the Company’s internal management reporting system or accounting records.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to or acquire the securities of the Company or any subsidiary of the Company, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This Presentation is not for publication, release or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction. This Presentation is confidential and intended solely for the use of intended recipients. Any reproduction or distribution by any means, including, but not limited to, visual or digital reproduction and distribution, is strictly prohibited. Absent express written agreement to the contrary, no Advisor acts in a fiduciary capacity for any recipient. Neither the Company nor its affiliates provide legal, accounting or tax advice. Accordingly, any statements contained herein as to tax matters were neither written nor intended by the Company to be used and cannot be used by any taxpayer for the purpose of avoiding tax penalties that may be imposed on such taxpayer. Each person should seek legal, accounting and tax advice based on his, her or its particular circumstances from independent advisors regarding the impact of the transactions or matters described herein.

Important Notice

The information contained in this Presentation is not to be viewed from nor for publication or distribution in nor taken or transmitted into the United States of America ("United States"), Australia, Canada or Japan and does not constitute an offer of securities for sale in any of these jurisdictions or elsewhere. Any securities offered by the Group have not been, and will not be, registered under the Securities Act, or the securities laws of any state or other jurisdiction of the United States and such securities may not be offered, sold, pledged, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, in or into the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. There will be no public offering of securities in the United States.

Accounting Restatement

In connection with preparations of a potential exit, the Company's management, together with its auditors PricewaterhouseCoopers, is currently re-evaluating the Company's application of certain accounting principles in its historical financial statements since the year ended December 31, 2017. As a result of this re-evaluation, the Company currently expects that it will decide to restate certain of its consolidated financial statements to facilitate a segment presentation in future periods, to present its former Russian business as discontinued operations, and/or to make certain ancillary changes (including for the years ended December 31, 2022 and 2021). Furthermore, the Company will report similar information in its future financial statements, starting with the consolidated financial statements as of and for the year ended December 31, 2023. Based on the initial findings of its ongoing assessment, management does not expect these changes to have a material cash impact on the Company's historical financial information. Management expects that any restatement will not result in material changes to the Company's historically reported EBITDA, Adjusted EBITDA or Pro Forma Adjusted EBITDA, and that there will be no material impact on the historical consolidated financial statements of the Company's indirect subsidiary, STADA Arzneimittel AG.

Cautionary Note Regarding Preliminary Financial Information

All financial results for the year ended December 31, 2023 and related comparisons to prior periods included in this Presentation are preliminary, have not been reviewed or audited, are based upon the Company's estimates, and were prepared prior to the completion of the Company's financial statement close process. These selected preliminary financial results should not be viewed as a substitute for the Company's final results, do not present all information necessary for an understanding of the Company's financial performance as of and for the year ended December 31, 2023, and should not be considered final until the Company delivers its audited consolidated financial statements as of and for the year ended December 31, 2023. During the course of the preparation of the Company's financial statements as of and for the year ended December 31, 2023, the Company may identify items that could cause its final reported results to be materially different from the preliminary financial information set forth in this Presentation. Accordingly, undue reliance should not be placed on this preliminary information. Once published, the relevant preliminary, unaudited financial figures for the financial year 2023 included in this Presentation will be superseded by the audited, published figures as of and for the year ended December 31, 2023.

STADA's has a clear purpose, vision and values

Purpose


**Caring for
People's Health**
as a Trusted Partner

Vision


To Be The **Partner of Choice**
in Consumer Healthcare,
Generics and Specialty while
Continuously Outgrowing the
Industry in Terms of
Sales and Profit

Values

Integrity
Entrepreneurship
Agility
One STADA



STADA has over 125 years of heritage, rooted in the pharmacy channel and with public market experience; take-private has transformed and positioned it for future growth



For over 125 years, STADA has stood for a high level of quality in the supply of pharmaceutical products and thus makes an important contribution to people's health


Source: Company information; IQVIA
 Note: (1) IFRS-reported net sales on the level of STADA group parent company Nidda German Topco GmbH for the continuing operations (i.e. excluding the former Russian subsidiaries of STADA Group). Financial data for the year ended December 31, 2023 is preliminary and unaudited; (2) CHC ranking based on internal analysis by STADA using data from the following source: IQVIA CH Customized Insights based on CORP data attribute and CHC classes 1-19, 97, sales value in LC€/PUB, calendar year 2023, reflecting estimates of real-world activity in 26 countries in Europe (excludes Russia and Sweden). Copyright IQVIA. All rights reserved; comparable IQVIA database for 2019; (3) Gx ranking based on internal analysis by STADA using data from the following source: IQVIA MIDAS® MAT/12/2023: sales values, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved; (4) Loss of exclusivity for a branded drug is the date when the patent expires and a generic competitor may enter the market; (5) Apo-Go®, Kinpeygo®, Lecigon®

STADA today: A pan-European leader in Consumer Healthcare, Generics and Specialty medicines with a track record of outperforming attractive markets

Net Sales FY23E⁽¹⁾	€3.7bn +13% vs. PY
Adjusted EBITDA⁽⁸⁾ FY23E⁽¹⁾	€0.8bn +19% vs. PY
Adjusted EBITDA⁽⁸⁾ Margin FY23E⁽¹⁾	~21%

Key stats

Top 4 CHC ⁽²⁾ and Gx ⁽³⁾ player in Europe	>200 Well positioned brands	~11.5k employees, incl. ~3.2k ⁽⁵⁾ Sales and Marketing across Europe
>110 countries where products are sold (no US exposure in Generics)	Large pipeline⁽⁴⁾ to drive future growth across all three segments	~41% of STADA's FY23E ⁽¹⁾ net sales are manufactured internally across 17 sites



Key attractive characteristics

Exposed to highly attractive markets	Organic and inorganic outperformance compared to its end-markets across all three segments
Entrepreneurial culture driving performance	Masters in managing complexity handling >24k SKUs, with no product representing more than 3.5% of net sales ⁽⁶⁾

Source: Company information, IQVIA

Note: (1) IFRS-reported values on the level of STADA group parent company Nidda German Topco GmbH for the continuing operations (i.e. excluding the former Russian subsidiaries of STADA Group). Financial data for the year ended December 31, 2023 is preliminary and unaudited; (2) Consumer Healthcare. CHC ranking based on internal analysis by STADA using data from the following source: IQVIA CH Customized Insights based on CORP data attribute and CHC classes 1-19, 97, sales value in LC€/PUB, calendar year 2023, reflecting estimates of real-world activity in 26 countries in Europe (excludes Russia and Sweden). Copyright IQVIA. All rights reserved; (3) Generics. Gx ranking based on internal analysis by STADA using data from the following source: IQVIA MIDAS® MAT/12/2023: sales values, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved; (4) Approved own developments and signed contract developments; (5) Including customer service and sales back-office as of Oct-23; (6) As of FY23E. Financial information for the year ended December 31, 2023 is preliminary and unaudited and have not been reviewed by our auditors; (7) Sourced from management planning system; (8) Adjusted EBITDA is EBITDA adjusted for special items and currency effects. Special items include legal expenses, restructuring expenses and other items of non-recurring nature which Management excludes in order to improve the comparability of the KPIs across years; currency effects are also adjusted to enhance comparability of the KPIs across the years

STADA has significant size and scale across its three segments



Overview	Non-prescription healthcare products	Off-patent prescription drugs sold under International Non-proprietary Name (INN)	Includes Branded / Specialty Generics (for chronic, complex, or rare diseases); Biosimilars; Innovative Medicines
Key differentiator	Expert in creating local brand heroes	Targeting >85% LoE coverage	Partner of choice with optionality to launch and grow innovative products across diverse TAs
Net sales 2023E⁽¹⁾	€1.5bn	€1.5bn	€0.7bn
STADA position⁽²⁾	#1 player in Germany ⁽²⁾ ; #1-3 positions for >200 brands in Europe, Eurasia & Emerging Markets ⁽²⁾	#4 Gx player in Europe ⁽³⁾ ; Top 3 positions in 7 countries, incl. Germany, Belgium, and Ireland ⁽³⁾	#1-3 positions in 3 biosimilars across several European markets ⁽⁴⁾ ; Gold standard treatment for late PD ⁽⁵⁾ ; Only treatment for orphan disease IgAN ⁽⁶⁾

Source: Company information

Note: (1) IFRS reported values on the level of STADA group parent company Nidda German Topco GmbH for the continuing operations (i.e. excluding the former Russian subsidiaries of STADA Group). Financial data for the year ended December 31, 2023 is preliminary and unaudited; (2) Based on IQVIA data for market position of brands including Sanofi Evolve Commercialization Alliance Agreement with >€0.5m sales across Europe, Eurasia, and Emerging Markets in FY23; (3) Ranking based on internal analysis by STADA using data from the following source: IQVIA MIDAS® MAT/12/2023: sales values, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved; (4) Based on IQVIA sales data for biosimilars across Europe in FY23; (5) Parkinson's disease; (6) Immunoglobulin A Nephropathy

STADA offers a compelling investment case in European Healthcare


	<p>1 Large, growing and resilient addressable markets of Consumer Healthcare, Generics & Specialty</p>	<p>~\$100bn European market⁽¹⁾ growing at high-single digits⁽²⁾</p>		
	<p>2 A leading integrated platform which is outperforming competition and growing faster than its relevant market⁽⁸⁾ driven by culture</p>	<p>#4 in EU in CHC⁽³⁾ & Gx⁽⁴⁾</p>	<p>>24k SKUs</p>	<p>110+ Countries served</p>
	<p>3 Highly integrated TechOps organization enables competitive cost across segments and products</p>	<p>17 sites</p>	<p>>70% Of top 50 APIs dual sourced</p>	<p>>1.1bn €220m Packages sold in 2023 TechOps savings⁽⁵⁾</p>
	<p>4 Fully invested and highly scalable platform with strong development and regulatory capabilities</p>	<p>880 launches in 2023 Pipeline with 2,500 Approval procedures for 200 APIs</p>		
	<p>5 Partner of choice for M&A and Licensing activity with demonstrated integration and acceleration capabilities</p>	<p>>20 M&A deals since 2018</p>		<p>364 BD&L deals since 2020</p>
	<p>6 Highly-skilled management team with track record of successful execution</p>	<p>Previous experience in leading institutions</p> 		
	<p>7 An ESG leader in the industry with a well-developed strategy aimed at long-term operational sustainability</p>	<p>Top 2% of pharma companies with the lowest ESG risk rating score⁽⁷⁾ rated by SUSTAINALYTICS</p>		
	<p>8 Attractive financial profile with track record of above market growth, healthy margins and cash flow</p>	<p>+13% Revenue growth 2022 – 2023E⁽⁶⁾</p>		<p>+19% Adj. EBITDA⁽⁸⁾ growth 2022 – 2023E⁽⁶⁾</p>

Sources: Company information; Company analysis as of March 2024; IQVIA; Euromonitor; Evaluate Pharma. Note: (1) Estimated size of CHC, Gx and Sx markets for 2023, based on IQVIA, Euromonitor and Evaluate Pharma; (2) Growth refers to 2023-2028 period; (3) CHC ranking based on internal analysis by STADA using data from the following source: IQVIA CH Customized Insights based on CORP data attribute and CHC classes 1-19, 97, sales value in LCE/PUB, calendar year 2023, reflecting estimates of real-world activity in 26 countries in Europe (excludes Russia and Sweden). Copyright IQVIA. All rights reserved; (4) Gx ranking based on internal analysis by STADA using data from the following source: IQVIA MIDAS® MAT/12/2023: sales values, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved; (5) During 2017-2022 timeframe; (6) Nidda German Topco GmbH – IFRS reported values for continuing operations. Financial information for the year ended December 31, 2023 is preliminary and unaudited and has not been reviewed by our auditors; (7) No. 7/428 rated companies in the pharmaceuticals sub-industry based on 2023 Sustainalytics ESG risk rating as per December 5th, 2023; (8) EU CHC, Gx and Sx; (8) Adjusted EBITDA is EBITDA adjusted for special items and currency effects. Special items include legal expenses, restructuring expenses and other items of non-recurring nature which Management excludes in order to improve the comparability of the KPIs across years; currency effects are also adjusted to enhance comparability of the KPIs across the years

1 STADA's addressable markets across Consumer Healthcare, Generics and Specialty are attractive, large, growing and highly resilient

THE CHC MARKET IS SIZEABLE & SET TO EXPERIENCE SUSTAINABLE GROWTH...

European CHC market growth outlook 2019-2028, EUR bn




MARKET GROWTH DRIVERS

- ✓ Ageing population
- ✓ Increasing market penetration across younger age cohorts
- ✓ Increasing shift to self care and prevention
- ✓ Low price elasticity

...WHILE THE MOMENTUM IN THE GX MARKET CONTINUES TO BUILD...

European Generics⁽¹⁾ market growth outlook 2019-2028, EUR bn




MARKET GROWTH DRIVERS

- ✓ Ageing population
- ✓ Regulatory tailwind
- ✓ 2025+ looming patent cliffs
- ✓ Increased value of upcoming LoEs⁽³⁾

...DRIVEN BY THE LAUNCH OF FURTHER SPECIALTY

European Specialty⁽²⁾ market growth outlook 2019-2028, EUR bn



MARKET GROWTH DRIVERS

- ✓ Growing prescription drug spending on chronic diseases
- ✓ Increasing market penetration across the world
- ✓ Large value of upcoming LoEs of Biologic and Specialty-Generic medicines⁽⁴⁾

Sources: Historical market data for the CHC market based on IQVIA OTCIMS and Euromonitor; for the Gx market based on IQVIA, and for the Sx market based on IQVIA and Evaluate Pharma. 2028 market estimates are based on the Company's analysis

Note: (1) Includes International Non-proprietary Name only; (2) Includes biosimilars, specialty generics, and branded generics; (3) Refers to value of Generics LoEs in terms of originator gross sales the year prior to loss of exclusivity based on IQVIA data; (4) Refers to value of Biologic and Specialty-Generic LoEs in terms of originator gross sales the year prior to loss of exclusivity based on IQVIA data

2

STADA is a market leader across its segments, and is outgrowing the markets in which it operates

Consumer Healthcare 40%

#1 in Germany⁽¹⁾; #1-3 positions⁽¹⁾ for >200 brands across categories in Europe, Eurasia & EM⁽²⁾

#1 dealmaker in CHC in Europe⁽³⁾

Selected products

Product	Therapeutical Area	Ranking ⁽¹⁾⁽⁴⁾
Grippostad	Cough & Cold	1
Duofilm	Derma	1
Cetirizine	Cough & Cold	1

Generics 40%

Supplies affordable Gx in EU in all essential categories

Selected products

Product	Therapeutical Area
Tilidin	Pain relief
Atorvastatin	Cholesterol and heart related diseases
Amoxi-Clavulan	Anti-infective




Specialty 20%

15 years of experience in biosimilars leveraged to continue driving growth in Gx

Selected products


Product	Therapeutical Area
LECIGON <small>levodopa, entacapone, carbidopa, biperiden, gel</small>	Late-stage Parkinson's Disease
SILAPO [®]	Anemia caused by chronic kidney failure and chemotherapy
KINPEYGO 4 mg <small>Modified-release hard capsules budesonide</small>	IgA Nephropathy

Market position



Sources: Financials as disclosed by company; Historical market data for the CHC market based on IQVIA OTCIMS and Euromonitor; for the Gx market based on IQVIA, and for the Sx market based on IQVIA and Evaluate Pharma
 Note: (1) Based on IQVIA data for market position of brands including Sanofi Evolve Commercialization Alliance Agreement with >€0.5m sales across Europe, Eurasia, and Emerging Markets in FY23; (2) Emerging Markets. Including Australia, New Zealand, China, UAE, Iraq, Kuwait, Oman, Qatar, Yemen, China, Hong Kong, Taiwan, Philippines, Vietnam, Bahrain, Jordan, Lebanon, Saudi Arabia, Thailand and others; (3) In terms of number of M&A deals, 2018-23; (4) In respective disease category; (5) IFRS-reported values on the level of STADA group parent company Nidda German Topco GmbH for the continuing operations (i.e. excluding the former Russian subsidiaries of STADA Group). Financial data for the year ended December 31, 2023 and December 31, 2019 is preliminary and unaudited; (6) Based on IQVIA OTCIMS and Euromonitor; (7) Based on IQVIA; (8) Based on IQVIA and Evaluate Pharma; (9) CHC ranking based on internal analysis by STADA using data from the following source: IQVIA CH Customized Insights based on CORP data attribute and CHC classes 1-19, 97, sales value in LCE/PUB, calendar year 2023, reflecting estimates of real-world activity in 26 countries in Europe (excludes Russia and Sweden). Copyright IQVIA. All rights reserved; (10) Gx ranking based on internal analysis by STADA using data from the following source: IQVIA MIDAS® MAT/12/2023: sales values, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved


2 STADA's integrated platform is uniquely positioned compared to its peer group



Source: Company information


Note: (1) Over the counter; (2) Indicative management view based on product offering of peers

2 STADA's resilient outperformance of the market is supported by its highly symbiotic segments, which drive meaningful synergies along the value-chain




2 STADA's growth culture is the key differentiator and a driver behind its performance

Constant improvement in employee engagement survey participation rates



Higher performance by units with strong responses in employee surveys



Unique cultural KPIs

~100 STADA+⁽¹⁾ business cases contributing >€30m in additional EBITDA in 2022

94% of employees stated that they are proud of Company's purpose (2023)⁽²⁾


52% women in management positions (2023)

89 Nationalities of employees (2023)

Source: Company information

Note: (1) STADA+ is a program to enable employees at all levels to pursue value-adding initiatives beyond regular budget process; (2) Based on pulse survey carried out in November 2023 across STADA employees; (3) Including Russian business carved out in 2023; (4) Financial data for the year ended December 31, 2023 is preliminary and unaudited; (5) According to Qualtrics benchmark EXM Methodology for Healthcare; (6) The X-axis represents survey score bands from Jupiter's pulse surveys, with scores ranging from 0 (not at all) to 10 (absolutely); the Y-axis shows the average next twelve months (NTM) net sales growth (%) (not weighted by net sales or number of FTEs), based on 2021-22 survey data from 224 country-time pairs; step lines on the graph indicate the average NTM net sales for groups of countries during specific survey periods, categorized by their score bands

3 TechOps is an integrated organization with a balanced internal and external network providing reliable, cost-competitive, and compliant supply across segments



Source: Company information

Note: (1) Figures referred to FY2023, unless stated otherwise; (2) As of Oct-23; (3) Based on number of transferred products; (4) OTIF: On time, in full; (5) Financial information for the year ended December 31, 2023 is preliminary and unaudited and has not been reviewed by our auditors

3

STADA's TechOps enables highly efficient cost control on both external supply operations and internal manufacturing footprint

STADA's approach to external supply operations realises significant savings



Proactive portfolio management with focus on supply harmonization



Full External Supply Operations integration across functions to embrace "external is internal" philosophy



Global KPI analytics for standardized reviews and performance evaluation




Consolidated TechOps spend, with 44% of external sourcing costs attributable to Strategic CMOs⁽¹⁾ in 2023E⁽²⁾, an increase from 39% in 2021



Strong cost management for production material, with >70% of top 50 APIs dual-sourced

Highly efficient and cost competitive manufacturing footprint, with the majority of plants in most cost competitive countries




Source: Company information

Note: (1) Contract Manufacturing Organization(s). CMOs include M&A & Commercial Alliance partners, Strategic CMOs and Local CMOs; (2) Based on number of sites

4

STADA has strong commercial infrastructure across all of Europe and several Emerging Markets – and a global reach in terms of BD&L – and Procurement

Full commercial coverage of Europe and emerging presence in selected high-growth markets



Source: Company information.

Note: (1) Financial information for the year ended December 31, 2023 is preliminary and unaudited and has not been reviewed by our auditors; (2) Global export and trade markets refers to countries where STADA actively manages distributors; (3) As of Oct-23

Global resources and capabilities

	44	Countries with local commercial teams that have industry-leading capabilities across Pharmacy, Physician, and Tender Go-to-market models
	Global presence	BD&L / Portfolio and Procurement staff in Europe, Asia and USA
	~3.2k	FTEs in STADA Commercial Functions ⁽³⁾
	~2.2k	FTEs in STADA Sales Force ⁽³⁾
	320	In-country customer-facing Specialty FTEs ⁽³⁾
	Lean HQ	Only 6% of FTEs in German HQ ⁽³⁾
	~21%	Marketing & Sales spend of total net sales in FY23E ⁽¹⁾

4 Strong development capabilities make STADA a leading innovator

Product Development Geographical Footprint and Set up

Site	Country	Product Development Capabilities
Huddersfield 		<ul style="list-style-type: none"> • Derma, Home & Hygiene, OTC • Liquid and Semi-Solids
Preston 		<ul style="list-style-type: none"> • Food Supplements
Reading 		<ul style="list-style-type: none"> • Parkinson's
Tulln 		<ul style="list-style-type: none"> • Consumer Healthcare
Vrsac 		<ul style="list-style-type: none"> • Generics: Small Molecules, H2M & VAM, SDF • Consumer Healthcare: SDF, liquids and semi-solids incl. food supplements
Trinec 		<ul style="list-style-type: none"> • Food supplements • Probiotics
Tuy Hoa 		<ul style="list-style-type: none"> • Generics: Local & regional markets • Small Molecules
Bad Vilbel 		<ul style="list-style-type: none"> • Consumer Healthcare

 Internal Development Center

 External Development Center

 Production site

Unique Product Development platform



657

R&D team members⁽¹⁾⁽²⁾



127

Product Development FTEs⁽²⁾



>85%

Targeted LoE⁽³⁾ coverage



>270

Projects under development



7

Internal Product Development centres



Sources: Company information, IQVIA, Expert interviews, Evaluate Pharma

Note: (1) All employees in R&D functions, e.g. including portfolio management & RA; (2) As of Oct-23; (3) Loss of exclusivity for a branded drug is the date when the patent expires and a generic competitor may enter the market. Target LoE considers European top 5 markets, HIV and respiratory LoEs not in scope as they are only considered opportunistically, LoE coverage based on gross sales of LoE molecule in LoE year, all molecules with STADA sales in IQVIA or concrete launch plans for 2023/2024 (e.g., Levosimendan, Dabigatran Etxilate) counted as covered

4

STADA has a track record of successfully creating value through pipeline development

Strong track record with launches⁽²⁾ contributing on average 4% of YoY growth since 2020




Strong CHC product development capabilities

€156m incremental sales from SKUs launches since 2019




Loss of Exclusivity⁽⁵⁾ (LoE) coverage

Target coverage of in-scope LoEs⁽⁶⁾



STADA's robust launch performance

Launch coverage of top 20 European LoEs⁽⁷⁾ within 2020-22




Sources: STADA; IQVIA; Evaluate Pharma; Expert interviews

Note: LoE dates based on the first SPC expiry in any European market, some national LoEs might occur earlier / later; All LoE values as originator gross sales, LoEs on country level. (1) Financial information for the year ended December 31, 2023 is preliminary and unaudited and has not been reviewed by our auditors; (2) Launches defined as new SKU for a country, including launching existing products in a new country (for example, bringing an existing product to a new country under a different brand); (3) Previous year; (4) Excluding Bortezomib; (5) Loss of exclusivity for a branded drug is the date when the patent expires and a generic competitor may enter the market; (6) European top 5 markets, HIV and respiratory LoEs not in scope as they are only considered opportunistically, LoE coverage based on gross sales of LoE molecule in LoE year, all molecules with STADA sales in IQVIA or concrete launch plans for 2023/2024 (e.g., Levosimendan, Dabigatran Etxelilate) counted as covered; (7) Top 20 European LoEs in terms of market value and with one of the top 4 European Gx players present

5

Strong global footprint and track-record make STADA the BD&L partner of choice for all 3 segments, allowing in-licensing at competitive terms



364
BD&L⁽¹⁾ Deals '20-'23E



>100
Development Partners across >25 countries

Highlights

- >100 Development Partners for Licensing Deals and >5 preferred partners for CHC
- “External becomes Internal”: 10 Strategic Partnerships with master agreements (e.g., possibility to internalise production after 3 to 5y)
- Strategic co-development and manufacturing with Chinese API partner for 14 Oncology LoEs (External Product Development)


Source: Company information
Note: (1) Business Development and Licensing

5

STADA has demonstrated itself to be Pharma's partner of choice for M&A with strong integration capabilities

M&A stats: **> 20 M&A deals** **€1.3bn investment⁽⁴⁾⁽⁵⁾** **200+ brands** **3,000+ SKUs**

Net Sales⁽⁴⁾



2018A	2019A	2020A	2021A	2022A	2023E ⁽¹⁾
Hedrin buy-back sanofi	Signing Takeda Takeda closing	Distribution I sanofi signing	Distribution II sanofi Go-live		
Nizoral Shampoo J&J	Signing Walmark MIDEUROPA closing	Sanofi Dragon sanofi	Nemus Lex PHARMOVAL	Femmabiotic FemmaBiotic	
Bioceuticals BIO	Signing FERN-C closing	Innventa INNventa	Nizoral Cream J&J	K-Lyte K-Lyte	
Ketodol ALFASIGMA	GSK I Violet GSK	GSK II Elara GSK		Sanofi Leopard sanofi	
	Biopharma biopharma	Lecigon Lobsor		Optipharm opti pharm	
	Optipharm opti pharm	Orasept BAYER			
		Hedrin buy-b. II mundipharma			

STADA the **go-to-partner** for Europe: **9 "serial deals"** with counterparties that transacted **more than once with STADA** since 2018

No. 1 dealmaker in CHC in Europe⁽²⁾

Strong top and bottom-line deal case outperformance

>250 M&A Tech transfers

COGS & OTIF⁽³⁾ improvements

Effective brand internationalization

Source: Company information, Biomedtracker

Note: Logos referring to counterparts or targets; years represent signing of agreement. (1) Financial information for the year ended December 31, 2023 is preliminary and unaudited and has not been reviewed by our auditors;

(2) Closed deals as of 12/2023, geography defined as either buy side or sell side HQ, yearly allocation by announcement date; based on Biomedtracker; (3) OTIF: On time, in full; (4) Includes Commercialization Alliance Agreements;

(5) Rounded figure; includes for asset deals estimated working capital; for Takeda pro-rata adjusted EV for purchase price relating to Russian business carved-out from STADA group (adjustment based on Contribution Margin 2023E)

6 Highly-skilled management team with a track record of successful execution

Name & position	Prior experience	Sector expertise		
		CHC	Gx	Sx
 Peter Goldschmidt Chief Executive Officer	  	✓	✓	✓
 Boris Döbler Chief Financial Officer	 	✓	✓	✓
 Simone Berger Chief People Officer	 	✓		
 Miguel Pagan Chief Technical Officer	  	✓	✓	✓
 Volker Sydow Global Consumer Healthcare	  	✓		
 Stephan Eder Western Europe & Germany	  	✓	✓	✓
 Bryan Kim Global Specialty	  			✓
 Yann Brun Global Dev, Portfolio, Reg, BD&L	  	✓	✓	✓
 Christos Gallis Eastern Europe	 	✓	✓	✓
 Stéphane Jacqmin Emerging Markets	   	✓	✓	✓

7 An ESG leader among top 2% of pharma companies⁽¹⁾ with a well-developed strategy and ambitious goals



Top 2% of pharma companies with the lowest ESG risk rating score⁽¹⁾ rated by



ESG governance structure with firm management commitment



2nd externally verified Sustainability Report released in 2023



ESG strategy aligned with 5 UN Sustainable Development Goals



-24% absolute GHG emissions (scope 1+2) reduction⁽²⁾ in 2023 vs. 2020



Target to decrease absolute carbon emissions (scope 1+2) by -42% until 2030 vs. 2020



Strong focus on operational health & safety (Accident rate⁽³⁾: 0.28 in 2023)



52% women in management positions in 2023

Sources: Stada Annual Report 2023, Stada Sustainability Report 2022 and Sustainalytics


Note: (1) No. 7/428 rated companies in the pharmaceuticals sub-industry based on 2023 Sustainalytics ESG risk rating as per December 5th, 2023; (2) Based on 2020 absolute Scope 1+2 GHG emissions of 131,619t of CO₂ equivalent and 2023 absolute Scope 1+2 GHG emissions of 99,700t of CO₂ equivalent (3) All production locations; accident rate calculated for every 200,000 working hours for accidents ≥1 lost day;

Above-market organic topline-growth, accretive EBITDA-growth at healthy margins and strong cash flow generation

Reported Net Sales

Net Sales growth by segment

- Sx +24%
- Gx +6%
- CHC +16%




Adjusted EBITDA⁽²⁾

Adjusted EBITDA⁽²⁾ margin by segment⁽³⁾


- Sx 31%
- Gx 25%
- CHC 25%

~21% Adjusted EBITDA⁽²⁾ margin



Strong Cash flow⁽⁴⁾ generation

>80% Cash conversion⁽⁵⁾
2023E⁽¹⁾



Source: Company information

Notes: IFRS-reported values on the level of STADA group parent company Nidda German Topco GmbH for the continuing operations (i.e. excluding the former Russian subsidiaries of STADA Group). (1) Financial data for the year ended December 31, 2023 is preliminary and unaudited; (2) Adjusted EBITDA is EBITDA adjusted for special items and currency effects. Special items include legal expenses, restructuring expenses and other items of non-recurring nature which Management excludes in order to improve the comparability of the KPIs across years; currency effects are also adjusted to enhance comparability of the KPIs across the years; (3) Segment adjusted EBITDA margin excludes central costs; (4) Cash flow is calculated as adjusted EBITDA - Net capex (including disposals of fixed assets and excluding BD&L / milestone payments, M&A acquisitions, business combinations, and disposals of consolidated companies and M&A assets); (5) Cash conversion calculated as (adjusted EBITDA - Net capex (including disposals of fixed assets and excluding BD&L / milestone payments, M&A acquisitions, business combinations, and disposals of consolidated companies and M&A assets)) / adjusted EBITDA

Building the foundation for long-term profitable and sustainable growth

Track record and platform to continue to outperform attractive markets which are growing at >5% p.a.

Further shift to higher margin consumer and specialty businesses

STADA

Continued investment in state-of-the-art technology and human capital

Selectively expand through business development, licensing and M&A